Is Lantheus Holdings, Inc. (LNTH) a Buy, Sell, or Hold?
NASDAQ : LNTH
Lantheus Holdings, Inc.
$100.95 USD
-$0.12 (-0.12%)
- Volume
- 2.04M
- Average Volume
- 972.5K
- Market Capitalization
- $6.57B
- P/E Ratio
- 23.98
- Dividend Yield
- 0.00%
- Price Target
- $102.50
- Year High
- $111.86
- Year Low
- $49.67
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.06
Company Overview
NASDAQ
Mary Anne Heino
Drug Manufacturers - Specialty & Generic
Healthcare
LNTH
1193
US
USD
Liquidity Metrics
0.44
3.06
2.89
1.77
0.00
Sales & Valuation
$1.54B
4.22
5.01
12.89
7.82
Profitability
$3.41
$233.56M
17.69%
23.32%
23.27%
11.40%
P/E Metrics
23.98
3.37
3.37
Analyst Price Target & Rating
$102.50
$120.00
$94.00
4/5
19 Analysts
-1.51%
Financial Health Scores
5.59
5/9
$691.38M
$2.41B
$1.1B
$382.78M
Key Metrics (TTM)
$6.55B
4.21
14.07
3.06
23.27%
11.03%
4.19%
7.76%
$43.75
88 days
Company Executives
| Name | Title |
|---|---|
| Ludger Dinkelborg | Head of Research & Development |
| Mark Richard Kinarney | Vice President of Investor Relations |
| Neil Holland | Vice President of Business Insights & Operations |
| Amanda Morgan | Chief Commercial Officer |
| Dorothy Barr | Senior Vice President of Manufacturing & Technical Operations |
| Kimberly Brown | Chief Accounting Officer |
| Mary Anne Heino | Interim CEO & Executive Chairperson |
| Daniel Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary |
| Robert J. Marshall Jr. | Chief Financial Officer & Treasurer |
| Thomas Reiner | Chief Science Officer |
| Lee Anne Howe | Chief Information Officer |
Poll Results
No votes yet today — be the first to share your view!
About Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular d ... isease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
2026-08-07 15:00:00
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 7, 2026
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
2026-08-07 14:16:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-08-07 12:00:00
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
2026-08-07 11:02:00
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Under the terms of the proposed transaction, shareholders of Lantheus will receive $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments,.
Lantheus Reports Second Quarter 2026 Financial Results
2026-08-06 07:00:00
Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second quarter of 2025 Announced on August 3, 2026 that it has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion BEDFORD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its second quarter ended June 30, 2026.
First Trust Advisors LP Purchases 44,713 Shares of Lantheus Holdings, Inc. $LNTH
2026-08-05 03:45:40
First Trust Advisors LP boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) by 287.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,258 shares of the medical equipment provider's stock after acquiring an additional
2026-08-03 16:00:00
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH) PR Newswire
2026-08-03 15:23:00
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH ) related to its sale to Curium US Holdings LLC.
Frequently Asked Questions
-
What is the current Lantheus Holdings, Inc. (LNTH) stock price?
-
Lantheus Holdings, Inc.(NASDAQ:LNTH) stock price is $100.95 in the last trading session. During the trading session, LNTH stock reached the peak price of $111.86 while $49.67 was the lowest point it dropped to. The percentage change in LNTH stock occurred in the recent session was --0.12% while the dollar amount for the price change in LNTH stock was -$0.12.
-
LNTH's industry and sector of operation?
-
The NASDAQ listed LNTH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of LNTH?
-
Ludger Dinkelborg | Head of Research & Development
Mark Richard Kinarney | Vice President of Investor Relations
Neil Holland | Vice President of Business Insights & Operations
Amanda Morgan | Chief Commercial Officer
Dorothy Barr | Senior Vice President of Manufacturing & Technical Operations -
How many employees does LNTH have?
-
Number of LNTH employees currently stands at 1193. LNTH operates from 201 Burlington Road, Bedford, MA 01730, US.
-
Link for LNTH official website?
-
Official Website of LNTH is: https://www.lantheus.com
-
How do I contact LNTH?
-
LNTH could be contacted at phone #978 671 8001 and can also be accessed through its website. LNTH operates from 201 Burlington Road, Bedford, MA 01730, US.
-
How many shares of LNTH are traded daily?
-
The average number of LNTH shares traded daily for last 3 months was 972.5K.
-
What is the market cap of LNTH currently?
-
The market value of LNTH currently stands at $6.57B with its latest stock price at $100.95